Germany has a new National Pharma Strategy aiming to transform the country into a more attractive destination for clinical research, pharmaceutical manufacturing, and drug development.
The new Act is introducing significant changes in the conduct of Clinical Trials with pharmaceuticals, medical devices, and in-vitro diagnostics and companion diagnostics.
In this short presentation, Germany’s “Medical Research Act”, Evnia summarizes the proposed changes. The Act will remain under public consultation until 22 February 2024.
